Key Takeaways
- Major U.S. stock indices closed higher, with the Dow Jones up 0.15%, the S&P 500 gaining 0.31%, and the Nasdaq leading the rally with a 0.70% increase.
- Pfizer (PFE) received early U.S. Federal Trade Commission (FTC) clearance for its Metsera acquisition, a crucial step forward in its strategy to enter the rapidly growing obesity drug market.
- Johnson & Johnson (JNJ) submitted an application to the U.S. FDA for Stelara® (ustekinumab) for the treatment of pediatric ulcerative colitis, aiming to expand the blockbuster drug's indications.
- The IMF forecasts U.S. economic growth to be 2.0% in 2025, while Goldman Sachs reports that cryptocurrency now comprises 1% of the world's investing portfolio.
- The White House has reportedly removed the Atlantic from its oil lease plans, and a federal prosecutor has alleged that Bitcoin ATMs are enabling cryptocurrency scams.
U.S. equity markets concluded the trading day on a positive note, with all three major indices posting gains. The Dow Jones Industrial Average unofficially closed up 69.54 points, or 0.15%, reaching 47,591.66. The S&P 500 advanced 21.48 points, or 0.31%, to 6,843.82, while the technology-heavy Nasdaq Composite saw the strongest performance, climbing 165.60 points, or 0.70%, to 23,746.74.
Corporate Developments in Pharmaceuticals
In the pharmaceutical sector, Pfizer (PFE) announced it has received early clearance from the U.S. Federal Trade Commission (FTC) for its acquisition of Metsera. This regulatory approval removes a significant hurdle for the $4.9 billion deal, which is expected to bolster Pfizer's pipeline in the competitive obesity and cardiometabolic disease market. The acquisition aims to leverage Metsera's next-generation incretin and amylin programs, including potential best-in-class injectables and oral candidates.
Separately, Johnson & Johnson (JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Stelara® (ustekinumab). The application seeks to expand the approval of the drug for the treatment of pediatric patients aged two years and older with moderately to severely active ulcerative colitis. This move could broaden the market for Stelara, which is already approved for several inflammatory conditions in adults and older children.
Economic Outlook and Cryptocurrency Trends
The International Monetary Fund (IMF) has projected that the U.S. economy will experience 2.0% growth in 2025. This forecast provides a snapshot of the anticipated economic landscape for the coming year.
Meanwhile, a report from Goldman Sachs indicates that cryptocurrency now accounts for 1% of the world's total investing portfolio. This highlights the increasing, albeit still relatively small, integration of digital assets into mainstream investment strategies.
However, the cryptocurrency space is not without its challenges. A federal prosecutor has alleged that Bitcoin ATMs are being utilized to facilitate cryptocurrency scams. This raises concerns about consumer protection and regulatory oversight within the rapidly evolving crypto market.
Energy Policy Shift
In other news, the White House has reportedly removed the Atlantic from its future oil lease plans, according to Politico. This decision signals a shift in federal energy policy, potentially impacting offshore oil and gas development along the U.S. East Coast.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.